OREANDA-NEWS. Spanish pharmaceutical company PharmaMar said that clinical trials of the drug Aplidin for the treatment of adult patients from coronavirus have shown the safety and effectiveness of the drug. This is stated in a press release published on the company's website on Friday, October 16.

It is noted that the study managed to achieve "a noticeable reduction in the viral load and C-reactive protein in patients."

"80.7% of patients were discharged before the end of the 15th day from the moment of hospitalization, and 38.2%-before the eighth day (according to the Protocol, they must stay in the hospital for at least seven days)," PharmaMar said. In this regard, the company expects that it will soon be possible to start the third phase of testing.

As it became known on October 9, the Spanish government approved the introduction of a high-alert regime in the Autonomous community of Madrid due to the spread of this infection. The measure will restrict entry and exit from the capital and nine other localities.

According to the Worldometer website, as of October 16, Spain registered 972,958 cases of coronavirus and 33,553 deaths over the entire period of the epidemic.